Suven Pharmaceuticals Limited has officially changed its name to Cohance Lifesciences Limited. The change took effect on May 7, 2025, following approval from the Ministry of Corporate Affairs, Government of India. This was done as part of a Scheme of Amalgamation.
As of 9:35 AM on May 8, 2025, Suven Pharmaceuticals share price was trading at ₹1,103.50, a 2.02% increase; the stock has gained 6.27% over the past six months and 30.96% over the past year.
The Name Clause in the company’s Memorandum of Association has been updated to reflect the new name. All mentions of “Suven Pharmaceuticals Limited” in the Memorandum and Articles of Association now read “Cohance Lifesciences Limited.”
The company will be filing necessary applications with the BSE Limited and the National Stock Exchange of India Limited to reflect the name change in stock exchange records. Until then, it will continue to trade under the existing scrip code (543064) and symbol (SUVENPHAR).
Read more: Best Pharma Stocks in May 2025: Neuland Labs, Suven Pharma, Laurus Labs and More – Based on 5-Yr CAGR!
Cohance Lifesciences continues to function as a contract development and manufacturing organisation (CDMO). The company provides custom synthesis, process research and development, and commercial manufacturing services for pharmaceutical and biotech firms globally.
As per data for the twelve months ending December 2024, the consolidated revenue for the company stood at USD 318 million. The company has reported margins and return on capital over the past five years.
In June 2024, the company acquired Sapala, which works in oligonucleotide technology. In December 2024, it acquired NJ Bio, a company focused on antibody-drug conjugate (ADC) development. Both acquisitions were intended to expand technical capabilities in specific areas.
The company is currently involved in over 100 active projects, including a number of late-stage development molecules.
The change in name from Suven Pharmaceuticals to Cohance Lifesciences is now in effect. Apart from the legal and formal updates, operations, financial reporting, and existing projects continue as before.
Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.
Investments in the securities market are subject to market risks, read all the related documents carefully before investing.
Published on: May 8, 2025, 1:19 PM IST
Team Angel One
We're Live on WhatsApp! Join our channel for market insights & updates
Get the link to download the App
